2017 Fiscal Year Final Research Report
Clinical usefulness of anti-M-type phospholipase-A-receptor antibodies in patients with membranous nephropathy and the comparison of three quantification methods
| Project/Area Number |
26461242
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Kidney internal medicine
|
|---|
| Research Institution | Tokyo Women's Medical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2018-03-31
|
| Keywords | 内科 / 免疫学 / 腎臓学 |
|---|
| Outline of Final Research Achievements |
We aimed to establish methods to measure anti-M-type phospholipase A2 receptor (PLA2R) antibodies, specific markers of primary membranous nephropathy (MN), and assess their clinical usefulness. We developed a western blot assay and a cell-based enzyme-linked immunosorbent assay (ELISA). Anti-PLA2R antibodies were detected in 52% of the patients with biopsy-proven primary MN using the western blot. The levels of proteinuria correlated with the anti-PLA2R antibody titers measured by the three methods. Anti-PLA2R antibodies were significantly associated with physicians’ decisions on immunosuppressive treatment. The titers of anti-PLA2R antibodies declined significantly following treatment. These results suggest the usefulness of anti-PLA2R antibody as a diagnostic, prognostic, and surrogate biomarker in primary MN. The three methods proved to be reliable, but their performances differ.
|
| Free Research Field |
臨床免疫学
|
